Testing HIV prevention medicine cabotegravir in newborns
Part of Immune system & allergy, Infections clinical trials.
This study tests a long-acting injectable HIV prevention medicine called cabotegravir in newborn babies who were exposed to HIV. The goal is to see if it can help protect them from getting HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The baby is at least 37 weeks old (full-term) and 10 days old or younger.
- The baby's birth weight was at least 2 kg (about 4.4 pounds).
- The baby has already started standard HIV prevention medicine.
- The mother has been taking dolutegravir (an HIV medicine) for at least 4 weeks before delivery.
- The mother is breastfeeding or plans to breastfeed.
- The mother has confirmed HIV infection and has given consent for herself and her baby.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
This trial tests whether an experimental HIV vaccine, given with an adjuvant to boost the immune response, is safe and produces an immune response in infants who were exposed to HIV in the womb but are not infected. The study aims to help protect these vulnerable infants.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.